entertainment -WSS

entertainment

author：entertainment 2025-10-01 18:34:14 - browse：254

Illumina, the largest maker of DNA-sequencing technology and a storied name in the biotechnology industry, named Jacob Thaysen, a 10-year-veteran at life sciences-tools firm Agilent, as its new CEO.

The appointment follows a bitter board fight that ended with the departure of Francis deSouza, who had been Illumina’s CEO since 2016. The battle, tipped off by Illumina’s troubled acquisition of cancer diagnostics firm Grail, had involved a proxy fight staged by activist investor Carl Icahn.

During the battle, there had been speculation that Jay Flatley, deSouza’s predecessor, could return. Under Flatley, Illumina had grown from an upstart to the dominant player in a field that has proved pivotal for medical research and delivered sizable returns to investors.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Idaho abortion case may prompt more restrictions in other states

leisure time

WSS

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

The nurse manager staffing crisis is hurting patients

Methadone doses haven’t kept up in the age of fentanyl

As JPM 2024 winds down, some health tech firms project optimism

Health and fitness trackers are measuring the wrong things

Wegovy trial has doctors encouraged over new possibilities

leisure time

entertainment

focus

Hollywood unions extend contract negotiations for actors

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Psychedelics group wrestles with new pharma identity

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

At least 13 dead in Texas as scorching temps continue

Risky weight loss products often used by teens globally, per study

Malaria cases in Florida and Texas: Here’s what you need to know

New Medicare drug pricing powers could soon be upended in court

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How I ended up pumping milk in a bathroom stall at JPM 2024

entertainment

DeSantis can now import cheaper drugs. But will Biden get credit?

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Generative AI mines health records to identify patients’ social needs

Doulas covered by Medicaid under New York's new plan

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

focus

knowledge

leisure time

hotspot